WINNERSH, UK--(Marketwired - Sep 29, 2015) - Vernalis PLC (LSE: VER); (OTC PINK: VNLPY)
29 September 2015
LSE: VER
Vernalis plc
Results Announcement for the 18 months ended 30 June 2015
Tuzistra™ XR US launch underway, transition to a commercial specialty pharmaceutical company on track Investment in NCE pipeline complete
Vernalis plc (LSE: VER) today announces its audited results for the 18 month period ended 30 June 2015 and unaudited results for the 12 month period ended 30 June 2015.
The Group changed its accounting reference date from 31 December to 30 June on 18 November 2014 to align the external reporting period with the seasonality of the US cough cold market, which will become a major component of the Group’s future commercial business following the approval and launch of Tuzistra™ XR. While the financial highlights and financial review below focus on the 12 months ended 30 June 2015 compared to the 12 months ended 30 June 2014, figures for the audited 18 month period to 30 June 2015 are also presented. The interim performance, for the first 6 months through to June 2014, was published on 5 August 2014.
Help employers find you! Check out all the jobs and post your resume.
